Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. Februar 2025 06:30 ET | Quelle: Veru Inc.

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

--Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as...
06. Februar 2025 08:30 ET | Quelle: Veru Inc.

Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025

MIAMI, FL, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
04. Februar 2025 11:00 ET | Quelle: Future Market Insights Global and Consulting Pvt. Ltd.

Joint Replacement Market to Reach USD 32.2 Billion by 2035 at a 4.7% of CAGR, driven by Rising Osteoarthritis Cases & Aging Population | Future Market Insights, Inc.

NEWARK, Del:, Feb. 04, 2025 (GLOBE NEWSWIRE) -- The global joint replacement market is poised for significant expansion over the next decade. Valued at USD 20.3 billion in 2025, it is projected to...
04. Februar 2025 08:30 ET | Quelle: Veru Inc.

Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
28. Januar 2025 16:05 ET | Quelle: Stryker Corporation

Stryker reports 2024 operating results and 2025 outlook

Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2024: Fourth Quarter Results Reported net sales increased...
27. Januar 2025 06:30 ET | Quelle: Veru Inc.

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

-- Study met primary endpoint: Enobosarm treatment resulted in statistically significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on...
23. Januar 2025 19:30 ET | Quelle: Future Market Insights Global and Consulting Pvt. Ltd.

Hip and Knee Reconstructive Market to Reach USD 41,071.4 Million by 2035, Growing at a 5.6% CAGR from 2025 to 2035 | FMI

NEWARK, Del, Jan. 23, 2025 (GLOBE NEWSWIRE) -- The hip and knee reconstructive market is set to witness robust growth from 2025 to 2035, fueled by technological advancements, increasing geriatric...
08. November 2024 16:05 ET | Quelle: Entera Bio Ltd.

Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates

JERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptides and small therapeutic proteins, today reported...
08. November 2024 09:00 ET | Quelle: Sana Biotechnology, Inc

Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates

Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology Enrolling patients...
25. September 2024 11:30 ET | Quelle: Future Market Insights Global and Consulting Pvt. Ltd.

The One Step RT-qPCR Kits Market is Poised for Significant Expansion, projected to Reach USD 180.0 Million by 2034 With a 4.9% CAGR, Driven by Advancements in Molecular Diagnostics

NEWARK, Del, Sept. 25, 2024 (GLOBE NEWSWIRE) -- The global one step RT-qPCR kits market is projected to grow steadily, reaching a market value of USD 111.1 million in 2024, with a projected CAGR of...

Vorherige Seite

Nächste Seite